NANGIOTX
NangioTx, Inc. has developed a proprietary injectable drug, V-10, that creates new blood vessels for the treatment of peripheral artery disease (PAD), for which there is currently no FDA-approved therapy. PAD is characterized by poor blood flow to the legs, which leads to tissue damage and ultimately limb amputation/death. V-10’s activity is localized, minimally invasive, reverses the disease, and is cost-efficient. We have secured IP and have "freedom to operate."
NANGIOTX
Industry:
Pharmaceutical
Founded:
2015-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.nangiotx.com
Total Employee:
11+
Status:
Active
Contact:
1 646-883-1386
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Office 365 Mail Google Apps For Business GoDaddy DNS
Investors List
MassChallenge
MassChallenge investment in Non Equity Assistance - NangioTx
